Aprea Therapeutics, Inc.
APRENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for APRE. That does not mean none is planned.
Get an email about APRE's next catalysts
Track Aprea Therapeutics (APRE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
APRE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.08 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
APR-246 + azacitidine
MDS
Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
High-grade Serous Ovarian Cancer
APR-246
Acute Myeloid Leukemia or Myelodysplastic Syndromes
ATRN-119
Advanced Solid Tumor
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
APR-246 (eprenetapopt) + Pembrolizumab
Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APR-246 + azacitidine | Phase 3 | MDS | - | - |
Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | High-grade Serous Ovarian Cancer | - | - |
APR-246 | Phase 2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | - | - |
ATRN-119 | Phase 2 | Advanced Solid Tumor | - | - |
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | - | - |
APR-246 (eprenetapopt) + Pembrolizumab | Phase 2 | Bladder Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Aprea Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Aprea Therapeutics, Inc.'s (APRE) pipeline across Phase 3, Phase 2. Its lead program is APR-246 + azacitidine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aprea Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Aprea Therapeutics, Inc. (APRE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track APRE biotech catalysts?→
Add APRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aprea Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.